盐酸缬更昔洛韦片的注意事项有什么？

When using the tablets, patients should try to avoid excessive use of Valganciclovir Hydrochloride Tablets. The basic requirement for overdose of Valganciclovir Hydrochloride Tablets is to strictly follow the recommended dosage, so as to avoid the occurrence of some adverse reactions. So, what are the precautions for taking Valganciclovir Hydrochloride Tablets?

1. Precautions for children: There is no safety and effectiveness data for these patients. Valganciclovir hydrochloride tablets are not recommended for use in children because the pharmacokinetics of valganciclovir hydrochloride tablets in such patients have not been established.

2. Precautions during pregnancy and lactation: Pregnancy medication category C. Since valganciclovir is rapidly converted into ganciclovir in large quantities, studies on its reproductive toxicity have not been repeated. In animal experiments, ganciclovir caused reduced fertility and teratogenicity. It is recommended that women of childbearing potential use effective contraceptive measures during treatment. Male patients are advised to use barrier contraception during treatment with valganciclovir hydrochloride tablets and for at least 90 days after discontinuation of treatment. There are no safety data on valganciclovir hydrochloride tablets during human pregnancy. Pregnant women should avoid the use of valganciclovir hydrochloride tablets unless the benefits to the mother far outweigh the potential harm to the fetus. The developmental effects of valganciclovir or cyclovir on the perinatal and postnatal infant have not been studied, but it must be considered that ganciclovir may be excreted in breast milk and cause serious adverse reactions in nursing infants. Therefore, when considering the possible benefits of valganciclovir hydrochloride tablets to nursing mothers, a decision should be made whether to interrupt medication or breast-feeding. 

3. Precautions for the elderly: There is no safety and effectiveness data for these patients.

4. The tenfold bioavailability of valganciclovir hydrochloride tablets measured by ganciclovir is 10 times higher than that of ganciclovir capsules. Valganciclovir hydrochloride tablets cannot replace ganciclovir capsules in a 1:1 ratio. Patients who previously used ganciclovir capsules and want to switch to valganciclovir hydrochloride tablets should be informed that there is a risk of overdose if they take more than the prescribed dose of valganciclovir hydrochloride tablets.

5. It is recommended to monitor the complete blood count and platelet count during treatment with Valganciclovir Hydrochloride Tablets. For patients with severe leukopenia, neutropenia, anemia and/or thrombocytopenia, it is recommended to use blood cell growth factor therapy and/or consider suspending medication. For patients with renal insufficiency, the dose needs to be adjusted based on creatinine clearance. For patients who have undergone hemodialysis, it is recommended to use intravenous ganciclovir preparations (rather than tablets) and calculate the dose according to the dose reduction formula on the approved ganciclovir prescribing information.